NASDAQ:KA Kineta (KA) Stock Price, News & Analysis → The biggest energy story ever? (From Porter & Company) (Ad) Free KA Stock Alerts $0.56 -0.01 (-1.76%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.55▼$0.6150-Day Range$0.34▼$2.6152-Week Range$0.33▼$5.39Volume157,067 shsAverage Volume287,646 shsMarket Capitalization$6.34 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Kineta alerts: Email Address Kineta MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,279.1% Upside$8.00 Price TargetShort InterestHealthy1.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.41) to ($1.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.05 out of 5 stars 3.5 Analyst's Opinion Consensus RatingKineta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKineta has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.23% of the float of Kineta has been sold short.Short Interest Ratio / Days to CoverKineta has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kineta has recently increased by 53.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKineta does not currently pay a dividend.Dividend GrowthKineta does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KA. Previous Next 1.4 News and Social Media Coverage News SentimentKineta has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kineta this week, compared to 1 article on an average week.Search Interest3 people have searched for KA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kineta insiders have not sold or bought any company stock.Percentage Held by Insiders29.80% of the stock of Kineta is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.32% of the stock of Kineta is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kineta are expected to grow in the coming year, from ($1.41) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kineta is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kineta is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKineta has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…For the full story, click here. About Kineta Stock (NASDAQ:KA)Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy, which is in preclinical development for advanced solid tumors, such as renal cell carcinoma, ovarian, and colorectal cancers. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.Read More KA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KA Stock News HeadlinesApril 25, 2024 | americanbankingnews.comKineta (NASDAQ:KA) Stock Price Down 7.4%April 18, 2024 | msn.comKineta (KA) Price Target Increased by 25.58% to 13.77May 1, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 9, 2024 | finanznachrichten.deKineta, Inc.: Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialApril 8, 2024 | globenewswire.comKineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialMarch 22, 2024 | finanznachrichten.deKineta, Inc.: Kineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 21, 2024 | globenewswire.comKineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | globenewswire.comKVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data ReportedMay 1, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.March 1, 2024 | bizjournals.comKineta CEO laid off as cutbacks leave biotech with 4 employeesFebruary 29, 2024 | msn.comKineta stock falls ~25.7% after co cuts workforce by 64%, including CEOFebruary 29, 2024 | globenewswire.comKineta Announces Restructuring and Exploration of Strategic AlternativesFebruary 22, 2024 | finance.yahoo.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumFebruary 22, 2024 | globenewswire.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumFebruary 14, 2024 | finance.yahoo.comKineta to Present at Upcoming Investor ConferencesFebruary 14, 2024 | globenewswire.comKineta to Present at Upcoming Investor ConferencesFebruary 7, 2024 | stockhouse.comKineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat SeriesJanuary 29, 2024 | finance.yahoo.comKA: Phase I/II UpdateJanuary 17, 2024 | finanznachrichten.deKineta, Inc.: Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid TumorsDecember 13, 2023 | finance.yahoo.comKineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for CancerDecember 12, 2023 | finance.yahoo.comKineta to Present at the Life Sciences Investor Forum December 14thNovember 28, 2023 | finance.yahoo.comKineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023November 9, 2023 | finance.yahoo.comKineta to Present at the 5th Annual Macrophage-Directed Therapies SummitNovember 8, 2023 | markets.businessinsider.comBuy Rating for Kineta Backed by Promising Drug Trials and Solid Financial PerformanceNovember 7, 2023 | msn.comKA: Third Quarter Results - MSNNovember 7, 2023 | finance.yahoo.comKA: Third Quarter ResultsNovember 6, 2023 | benzinga.comKineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingSee More Headlines Receive KA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kineta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/01/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KA CUSIPN/A CIK1445283 Webwww.kinetabio.com Phone(206) 378-0400FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,317.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,100,000.00 Net MarginsN/A Pretax Margin-258.65% Return on Equity-453.89% Return on Assets-118.90% Debt Debt-to-Equity Ratio0.05 Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$5.44 million Price / Sales1.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book1.95Miscellaneous Outstanding Shares11,350,000Free Float7,695,000Market Cap$6.41 million OptionableNot Optionable Beta0.52 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Craig W. Philips (Age 63)President Comp: $485.79kMs. Pauline Kenny Esq. (Age 50)J.D., Advisor Comp: $349.72kMr. Keith A. Baker (Age 57)Chief Financial Officer Dr. Thierry Guillaudeux Ph.D. (Age 57)Chief Scientific Officer Gary GentgesExecutive Vice President of Corporate DevelopmentKey CompetitorsProcessa PharmaceuticalsNASDAQ:PCSAYumanity TherapeuticsNASDAQ:YMTXAinosNASDAQ:AIMDProtagenic TherapeuticsNASDAQ:PTIXKintara TherapeuticsNASDAQ:KTRAView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 104,208 shares on 2/13/2024Ownership: 7.948%Raymond J BartoszekBought 250 shares on 12/6/2023Total: $1,125.00 ($4.50/share)Raymond J BartoszekBought 1,000 shares on 12/4/2023Total: $4,330.00 ($4.33/share)Shawn IadonatoBought 900 shares on 11/28/2023Total: $2,997.00 ($3.33/share)Craig W PhilipsBought 3,000 shares on 11/28/2023Total: $9,810.00 ($3.27/share)View All Insider TransactionsView All Institutional Transactions KA Stock Analysis - Frequently Asked Questions Should I buy or sell Kineta stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kineta in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KA shares. View KA analyst ratings or view top-rated stocks. What is Kineta's stock price target for 2024? 1 analysts have issued 12-month price targets for Kineta's stock. Their KA share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 1,279.1% from the stock's current price. View analysts price targets for KA or view top-rated stocks among Wall Street analysts. How have KA shares performed in 2024? Kineta's stock was trading at $3.63 on January 1st, 2024. Since then, KA shares have decreased by 84.0% and is now trading at $0.5801. View the best growth stocks for 2024 here. Are investors shorting Kineta? Kineta saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 95,100 shares, an increase of 53.9% from the March 31st total of 61,800 shares. Based on an average trading volume of 359,200 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.2% of the shares of the company are sold short. View Kineta's Short Interest. When is Kineta's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KA earnings forecast. How were Kineta's earnings last quarter? Kineta, Inc. (NASDAQ:KA) released its quarterly earnings results on Thursday, March, 21st. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.10. How do I buy shares of Kineta? Shares of KA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KA) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlace😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kineta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
